5 – 6 December 2024
Virtual, broadcast from Munich, Germany

Scientific Programme

Thursday, 5 December 2024
Virtual
15:30 - 15:40 CET
Welcome and IntroductionSchnell O (Munich, Germany)
15:40 – 17:15 CET
Cardiovascular, kidney and metabolic care: Current and future perspectivesChair: Van Gaal L (Antwerp, Belgium), Fioretto P (Padua, Italy)
15:40 – 15:55
Update on the treatment of heart failure - new approaches, new outcomesKosiborod M (Kansas City, USA)
15:55 – 16:10
Chronic kidney disease: Cornerstones of today´s treatment and opportunities for the futureFernández-Fernández B (Madrid, Spain)
16:10 – 16:25
The next decade in the treatment of obesityMcGowan B (London, UK)
16:25 – 16:45
Organ Cross-Talk and Person-Centered Management of Obesity, CKD, Lipid Disorders, and DiabetesMüller-Wieland D (Aachen, Germany)
16:45 – 17:00
Microplastics and nanoplastics (MNPs): An emerging risk factor for cardiovascular diseaseCeriello A (Milan, Italy)
17:00 – 17:15
Discussion
17:15 – 17:30 CET
Break
17:30 – 18:45 CET
Updates from the Taskforce of the Guideline WorkshopChair: Rodbard H (Rockville, USA), Rydén L (Stockholm, Sweden)
17:30 – 17:45
The Taskforce of the Guideline Workshop: Aims and outcomesSchnell O (Munich, Germany)
17:45 – 18:00
Towards standardization of patient reported outcomes (PROs)Barnard-Kelly K (Hampshire, UK)
18:00 – 18:15
Disparities in prevalence and treatment of diabetes, cardiovascular and chronic kidney diseasesGavin J.R. (Atlanta, USA)
18:15 – 18:30
Network meta-analyses and clinical guidelines: what is missing for a precision medicine approach Giorgino F (Bari, Italy)
18:30 – 18:45
Panel discussion
18:40 – 19:00 CET
Break
19:00 – 20:00 CET
Cardio-renal metabolic diseases: How can we connect the dots?Chair: Jarvis S (London, UK)
Satellite Symposium kindly supported by Boehringer Ingelheim
19:00 – 19:03
Welcome and introduction Jarvis S (London, UK)
19:03 – 19:13
Why does connecting the dots matter in CRM diseases?Marx N (Aachen, Germany)
19:13 – 19:23
Connecting the dots in understanding CRM disease: does aldosterone have a role?Groop P-H. (Helsinki, Finland)
19:23 – 19:33
Connecting the dots in CRM disease: how do we work together?Jarvis S (London, UK)
19:33 - 19:58
Panel discussion
19:58 - 20:00
Closing remarks/final thoughtsJarvis S (London, UK)
20:00 – 20:45 CET
Oral Presentations – Part 1Chair: tbd
20:45 CET
Closing of Day 1
Friday, 6 December 2024
Virtual
08:30 – 09:30 CET
Type 1 Diabetes – Early detection and preventive treatment approachesChairs: Mathieu C (Leuven, Belgium), Moser O (Bayreuth, Germany)
08:30 – 08:45
Early detection of Type 1 Diabetes - risk evaluation, markers and early diagnosis programsDanne T (Lissabon, Portugal)
08:45 – 09:00
Treatment strategies for delaying the onset of Type 1 DiabetesDayan C.M. (Cardiff, UK)
09:00 – 09:15
Future directions in the treatment of CKD in Type 1 Diabetes Heerspink H (Groningen, Netherlands)
09:15 – 09:30
Discussion
09:30 – 10:45 CET
Advancing diabetes management through technological innovationsChairs: Battelino T (Ljubljana, Slovenia), Catrinoiu D (Constanta, Romania)
09:30 – 09:45
Continuous glucose monitoring in Type 2 DiabetesDel Prato S (Pisa, Italy)
09:45 – 10:00
CGM and cardiovascular perspectivesLandmesser U (Berlin, Germany)
10:00 – 10:15
CGM, hypoglycemia and risk predictionHeinemann L (San Diego, USA)
10:15 – 10:30
Automated Insulin delivery (AID), physical activity and exercise in Type 1 DiabetesMoser O (Bayreuth, Germany)
10:30 – 10:45
Discussion
10:45 – 11:00 CET
Break
11:00 – 12:00 CET
CKD and heart failure: current perspectives on diagnosis and treatmentChair: Groop P.-H. (Helsinki, Finland), tbd
11:00 – 11:15
UACR and eGFR: barriers of implementationSchaeffner E (Berlin, Germany)
11:15 – 11:30
KDIGO guidelines 2024: consistence with ESC?Jadoul M (Brussels, Belgium)
11:30 – 11:45
REVOLUTIONizing heart failure diagnosisAnderson L (London, UK)
11:45 - 12:00
Discussion
12:00 – 12:30 CET
Diabetes and the heart: exploring effects beyond heart failureChair: Papanas N (Alexandroupolis, Greece), Mankovsky B (Kyiv, Ukraine)
12:00 – 12:10
Cardiac autonomic neuropathy: current experimental and clinical practice considerationsStirban A (Birkenwerder, Germany)
12:10 – 12:20
Mitochondrial metabolomics and the diabetic heartStandl E (Munich, Germany)
12:20 – 12:30
Discussion
12:30 – 13:30 CET
Primary care at the forefront of cardiorenal and metabolic disease managementChair: Patel D (London, UK), Topsever P (Istanbul, Turkey)
12:30 – 12:45
Cardiovascular Risk evaluation in primary careKanumilli N (Manchester, UK)
12:45 – 13:00
Interconnectedness of Heart, Kidney and Metabolism – Perspectives of PCPsCos X (Barcelona, Spain)
13:00 - 13:15
Empowering diabetes self-management: the path to successMilenkovic T (Skopje, Macedonia)
13:15 - 13:30
Discussion
13:30 - 14:00 CET
Break
14:00 – 14:45 CET
Targeting obesity – combating metabolic diseasesChairs: Busetto L (Padua, Italy), Blueher M (Leipzig, Germany)
14:00 – 14:15
Obesity as a therapeutic target in heart failure therapyVan Gaal L (Antwerpen, Belgium)
14:15 – 14:30
GIP/GLP-1 receptor agonists – a new dawn in sleep apnea therapy?tbd
14:30 – 14:45
Discussion
14:45 - 15:30 CET
Eating for Health: Nutritional Strategies in Metabolic and Cardiovascular CareChair: tbd, Rahelić D (Zagreb, Croatia)
14:45 - 15:00
On the Path to Precision Nutrition in Cardiometabolic Diseasestbd
15:00 - 15:15
Navigating Nutrition under Incretin-Based TherapiesAlmandoz J (Texas, USA)
15:15 - 15:30
Discussion
15:30 - 16:15 CET
Liver in the Spotlight: Current Practices and New HorizonsChair: Tacke F (Berlin, Germany), tbd
15:30 - 15:45
Diagnosis and Treatment of MASLD: Current State of the ArtSpearman W (Cape Town, South Africa)
15:45 - 16:00
The liver – a new target for incretin therapies?Tacke F (Berlin, Germany)
16:00 - 16:15
Discussion
16:15 - 16:30 CET
Break
16:30 - 17:30 CET
Industry´s perspective - Panel Discussion
17:30 – 18:30 CET
Oral Presentations – Part 2Chair: tbd
18:30 – 18:45 CET
Abstract Awards and ClosingSchnell O (Munich, Germany)